Header Logo

Connection

PEDRO TOMAS RAMIREZ to Bortezomib

Back to Details
This is a "connection" page, showing publications PEDRO TOMAS RAMIREZ has written about Bortezomib.
PEDRO TOMAS RAMIREZ
Connection Strength
0.066
Bortezomib
  1. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.